Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Obesity Research & Clinical Practice|October 24, 2025
Under-documentation of diagnosis and follow-up procedures for overweight and obesity compared to other cardiovascular risk factors in hospitalised patients: A single centre, retrospective analysisJosefine Ruder, Lukas Schilliger, Athanasios Kogias, et al.Clinical Transplants|June 8, 2010
Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatmentMarkus Wahrmann, Michael Haidinger, Johannes Drach, et al.Journal of Diabetes and Its Complications|August 13, 2015
Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitusJohannes Werzowa, Giovanni Pacini, Manfred Hecking, et al.Journal of the American Society of Nephrology : JASN|February 22, 2003
Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipientsIrmgard Neumann, Michael Haidinger, Heidemarie Jäger, et al.World Journal of Urology|April 11, 2015
Histopathology and prognosis of de novo bladder tumors following solid organ transplantationInes A Ederer, Ilaria Lucca, Sebastian L Hofbauer, et al.Transplantation|February 6, 2013
Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trialJohannes Werzowa, Manfred Hecking, Michael Haidinger, et al.Wiener Klinische Wochenschrift|June 30, 2009
Vienna experience of ABO-incompatible living-donor kidney transplantationMichael Haidinger, Sabine Schmaldienst, Günther Körmöczi, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2014
Molecular regulation of the renin-angiotensin system in haemodialysis patientsJohannes J Kovarik, Marlies Antlanger, Oliver Domenig, et al.Transplant Immunology|December 2, 2006
Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipientsBernhard M Kirsch, Michael Haidinger, Maximilian Zeyda, et al.Trials|October 8, 2010
A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantationMichael Haidinger, Johannes Werzowa, Hans-Christian Voigt, et al.Pageof 4